UNASSIGNED: A retrospective evaluation of the clinical data of 78 patients with BCLC stage C HCC who received either TACE-sorafenib (TS) combination therapy or TACE monotherapy as their first treatment was done. The two groups were compared in terms of radiological tumor response 1 month after the intervention. The two groups were also compared in terms of time to progression (TTP), overall survival (OS), and adverse events.
UNASSIGNED: The disease control rate (44.9% and 25.8%, respectively, P = 0.09) was higher in the TS combination group than in the TACE monotherapy group after 1 month of treatment. The TS combination group had significantly superior TTP and OS than the TACE group (TTP was 4.6 and 3.1 months, respectively, P = 0.001), and OS was 10.1 and 7.8 months, respectively, P < 0.001). The TACE-S group had a greater cumulative survival time at 6 months, 9 months, and 1 year than the TACE group (97.9%, 51.1%, 25.7% vs. 90.4%, 51.6%, and 0%, respectively).
UNASSIGNED: TS combination therapy in advanced-stage (BCLC-C) HCC significantly improved disease control rate, TTP, and OS compared with TACE alone, without any significant increase in adverse reactions.
■对78例BCLCC期HCC患者的临床数据进行回顾性评估,这些患者接受TACE-索拉非尼(TS)联合治疗或TACE单药治疗作为其首次治疗。干预后1个月比较两组肿瘤的放射学反应。比较两组患者的进展时间(TTP),总生存期(OS),和不良事件。
■疾病控制率(44.9%和25.8%,分别,治疗1个月后,TS组合组的P=0.09)高于TACE单药治疗组。TS联合组TTP和OS明显优于TACE组(TTP分别为4.6和3.1个月,分别,P=0.001),OS分别为10.1和7.8个月,分别,P<0.001)。TACE-S组在6个月时的累积生存时间更长,9个月,和1年比TACE组(97.9%,51.1%,25.7%与90.4%,51.6%,0%,分别)。
■TS联合治疗晚期(BCLC-C)HCC可显着提高疾病控制率,TTP,和操作系统与单独的TACE相比,没有任何显著增加的不良反应。